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As the second cause of death and cognitive decline in industrialized countries,
stroke is a major burden for society. Vascular risks factors such as hypertension
and diabetes are involved in most stroke patients, aggravate stroke severity, but are
still poorly taken into account in preclinical studies. Microangiopathy and sustained
inflammation are exacerbated, likely explaining the severity of stroke in those patients.
We sought to demonstrate that intravenous administration of human adipose derived-
mesenchymal stem cells (hADMSC) that have immunomodulatory properties, could
accelerate sensorimotor recovery, prevent long-term spatial memory impairment and
promote neurogenesis, in diabetic or hypertensive mice, subjected to permanent middle
cerebral artery occlusion (pMCAo). Diabetic (streptozotocin IP) or hypertensive (L-NAME
in drinking water) male C57Bl6 mice subjected to pMCAo, were treated by hADMSC
(500,000 cells IV) 2 days after cerebral ischemia induction. Infarct volume, neurogenesis,
microglial/macrophage density, T-lymphocytes density, astrocytes density, and vessel
density were monitored 7 days after cells injection and at 6 weeks. Neurological
sensorimotor deficit and spatial memory were assessed until 6 weeks post-stroke.
Whatever the vascular risk factor, hADMSC showed no effect on functional sensorimotor
recovery or cognitive decline prevention at short or long-term assessment, nor
significantly modified neurogenesis, microglial/macrophage, T-lymphocytes, astrocytes,
and vessel density. This work is part of a European program (H2020, RESSTORE). We
discuss the discrepancy of our results with those obtained in rats and the optimal cell
injection time frame, source and type of cells according to the species stroke model.
A comprehensive understanding of the mechanisms preventing recovery should help for
successful clinical translation, but first could allow identifying good and bad responders
to cell therapy in stroke.
Keywords: stroke, cell therapy, adipose tissue, cognitive decline, inflammation, behavior
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INTRODUCTION
Stroke is currently the second cause of death and cognitive
decline worldwide (Snyder et al., 2015; World Health
Organization [WHO], 2018). Recanalization treatments,
either by rtPA (recombinant tissue plasminogen activator)
or thrombectomy, can only be used at the acute phase,
with less than 10% of patients being concerned (Bhaskar
et al., 2018). In that context, cell therapy, using stem cells/
progenitors or differentiated cells, was developed in order to
potentially repair tissue damage and improve neurological
outcome taking advantage of a wider therapeutic window
(Mangin and Kubis, 2018).
Among them, mesenchymal stem cells (MSCs) are particularly
attractive. They are multipotent cells capable of differentiating
into at least one differentiated cell type depending on
environmental conditions (Chamberlain et al., 2007). These
cells improve neurological deficit after stroke in both mice
(Chen et al., 2003) and rats (Li et al., 1999; Cho et al.,
2012) but their mechanism of action is still poorly understood,
although neurogenesis, angiogenesis and immunomodulation, all
contributing to new neuronal networks formation, have been
associated to improved neurological recovery (Chen et al., 2014).
Mesenchymal cells derive from multiple sources such as bone
marrow, cord blood, or adipose tissue, this last one offering
numerous advantages. A large number of cells can be easily
collected by liposuccion. Expansion of cells is easier than when
MSC are derived from bone marrow (BM-MSC), the other largest
source of MSC and they could be more effective than BM-MSC
(Mangin et al., 2019). Indeed, they proliferate better in vitro and
further reduce the cerebral ischemic-related damage in a mouse
model of transient middle cerebral artery occlusion (tMCAo)
compared to cells isolated from bone marrow (Ikegame et al.,
2011). In addition, they showed an excellent safety profile in
8 clinical trials representing 321 patients (Lalu et al., 2012)
and their low immunogenicity after allogeneic administration
(Pers and Jorgensen, 2013) make them a likely “ready-to-use”
therapeutic product.
Up to date, few studies have considered the impact of
vascular risk factors on stroke outcome. This is quite surprising
since hypertension, the first leading vascular risk factor for
stroke, is still dramatically underdiagnosed, with only 32.5%
of hypertensive patients being pharmacologically treated and
controlled (Chow et al., 2013). Diabetes is another independent
risk factor for stroke, tripling its incidence (Mankovsky and
Ziegler, 2004). These data are particularly alarming since the
diabetic population will double by 2030 (Shaw et al., 2010). These
two vascular risk factors are associated with increased disability,
death (Knopman et al., 2001; Ettehad et al., 2016) and post-
stroke cognitive decline (Gorelick et al., 2011). As hypertensive
and diabetic patients are at higher risk of stroke and therefore
potential candidates for cell therapy, understanding how vascular
risk factors influence donors’ cells properties and efficiency is
therefore mandatory (Mangin and Kubis, 2018).
This work if part of a H2020 program (RESSTORE) that
includes clinical and preclinical work-packages, and whose aim
is to assess the efficiency of cell therapy in stroke taken into
account vascular risk factors. Preclinical evaluation complied
with the STAIRS (Liu et al., 2009) and STEPS II (Savitz
et al., 2011) recommendations. Mesenchymal stem cells derived
from human adipose tissue (hADMSC) obtained from healthy
donor, were injected intravenously 2 days after induction of
a focal cerebral ischemia in mice in which hypertension or
diabetes had been previously induced. The primary objective
of our work was to evaluate the short (1 week) and long-
term (6 weeks) consequences on neurological sensorimotor
and cognitive decline and on stroke volume. Neurogenesis,
inflammation, and angiogenesis were secondarily evaluated.
MATERIALS AND METHODS
All experiments and surgical procedures were performed
according to the European Community Directive (2010/63/EU),
the ARRIVE (Animal Research Reporting In Vivo Experiments)
guidelines, and the French national guidelines for the care and
use of laboratory animals. The study was specifically approved by
our local institutional ethics committee (CE121#/17581v6) and
by the French ministry of Higher Education for Research and
Innovation (APAFIS#5431-2016031912549126 v2).
Experimental Design
The experimental design is summarized in Figure 1. Experiments
were performed on male adult C57/BL6 mice (Janvier Labs, Le
Genest-Saint-Isle, France) housed in a 12 h/light/dark cycle with
food and water ad libitum. Prior to stroke, either hypertension or
diabetes was induced. The duration of sustained hyperglycemia
and elevated blood pressure were determined to be the minimal
duration to induce an increased sensorimotor deficit compared to
age-matched mice without vascular risk factors. Because timing
differed between diabetic (2 months) and hypertensive mice
(4 months), control groups were matched with age. At day 0 (D0),
permanent occlusion of middle cerebral artery was performed.
At day 1 (D1), mice undergone cerebral MRI to be randomized
in treated or untreated groups, according to the infarct volume
and IV hADMSC or PBS were intravenously (IV) delivered the
day after (D2). Sensorimotor evaluation was conducted from D-1
until D14, open field at D28 and cognitive assessment between
D30 and D38. Stroke volume measured after Cresyl violet
staining was assessed at day 9 (7 days after hADMSC delivery)
and neuroblasts density, microglia/macrophages cells density,
T-Lymphocytes density, astrocytes density, and vessels density
assessment were performed 1-week post-hADMSC delivery
(9 days post-stroke, D9) or 40 days post-stroke (D40), i.e., at
the end of the cognitive assessment period, to evaluate the
histological consequences of hADMSC injection. Thus, a subset
of mice was sacrificed at D9 and another at D40 for histological
and immunohistochemical analyses.
The following groups were evaluated: untreated non-diabetic
(ND-PBS) and diabetic (D-PBS) mice and treated non-diabetic
(ND-hADMSC) and diabetic (D-hADMSC) mice; untreated
non-hypertensive (NHT-PBS) and hypertensive (HT-PBS) mice
and treated non-hypertensive mice (NHT-hADMSC) and
hypertensive mice (HT-hADMSC).
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FIGURE 1 | Experimental protocol and time schedule for hypertensive and diabetic mice. hADMSC, human adipose derived mesenchymal stem cells; pMCAo,
permanent, middle cerebral artery occlusion; n, number of mice.
In a separate set of diabetic and hypertensive mice,
vasoreactivity was assessed after 8 weeks of diabetes and
hypertension induction, by measuring with Doppler ultrasound
the variations of mean blood flow velocity at the basilar trunk
after CO2 inhalation.
All experiments were conducted by investigators blinded to
the status (diabetic and non-diabetic, hypertensive, and non-
hypertensive) and the treatment (hADMSC or PBS).
Diabetes Induction
At 6 weeks of age, C57Bl6/J mice were randomized to receive
for five consecutive days intraperitoneal (IP) injections of STZ
(60 mg/kg in 100 µL of citrate buffer) to induce diabetes or
100 µL of citrate buffer for non-diabetic mice. To ensure that
mice became diabetic, blood glucose levels were monitored once
a week by collecting blood through a skin incision at the tail.
Only mice with sustained hyperglycemia above 300 mg/dL were
considered as diabetic (90% of treated mice).
Hypertension Induction
At 6 weeks of age, C57Bl6/J mice were randomized to
receive during 16 weeks L-NAME [N(G)-nitro-L-arginine
methyl ester, 60 mg/kg/day] in drinking water to induce
hypertension, or without L-NAME for the non-hypertensive
mice. Systolic and diastolic blood pressure and heart rate
were measured after 2 weeks of habituation once a week
until sacrifice, using a tail-cuff plethysmograph connected
to a computerized system (BP-2000 computerized system,
Visitech Systems, Apex, NC, United States). Measurements were
performed in vigil mice, placed on a heating blanket. All mice
became hypertensive.
Doppler Imaging of Cerebral
Vasoreactivity to Inhaled CO2
Cerebral vasoreactivity was assessed in all groups after 8 weeks
of hyperglycemia and hypertension induction as previously
described (Poittevin et al., 2015). This time point was previously
determined in preliminary studies to be the shortest time to
impair vasoreactivity. Ultrasound measurements were performed
under 0.5% isoflurane anesthesia, using an echocardiograph
(Acuson S3000, Siemens, Erlangen, Germany), equipped with a
14-MHz probe (14L5 SP). As previously described, time-averaged
mean blood flow velocities were measured at the basilar trunk
under air and after 5 min of breathing a gas mixture of 16% O2,
5% CO2, and 70% N2.
Permanent Middle Cerebral Artery
(pMCAo) Induction
This procedure has already been fully described (Poittevin et al.,
2013). Briefly, at D0, mice were anesthetized by isoflurane
(initially 2%, followed by 1.5 to 1.8% in O2) and body temperature
was continuously maintained at 37 ± 0.5◦C during the whole
procedure using a heating blanket (Homeothermic Blanket
Control Unit; Harvard Apparatus Limited, United Kingdom).
The permanent focal cerebral ischemia was induced by
electrocoagulation of the left middle cerebral artery. The whole
procedure did not exceed 10 min.
Cerebral MRI
MR examinations were performed at D1 at the FRIM plateform
using a 7.0 Tesla MR unit (PharmaScan, Bruker Biospin,
Ettlingen, Germany) equipped with a surface coil with an
internal diameter of 10 mm, in thermoregulated and anesthetized
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(2% isoflurane in O2) mice. T2-weighted imaging [Rapid Imaging
with Refocused Echoies (RARE) sequence was used with the
following parameters: effective TE: 33 ms, TR: 2742 ms, NEX: 1,
Flip angle: 180◦] was performed in order to measure infarct
volume (Medical Image Processing, Analysis and Visualization
or MIPAV software, NIH, Bethesda, MD, United States) and T2∗-
weighted imaging [a Fast Low Angle Shot (FLASH) sequence was
used with the following parameters: 15 axial slices 1 mm thick,
TE: 8 ms, TR: 600 ms, NEX: 2, Flip angle: 30◦, FOV: 2 cm× 2 cm,
MTX: 256 × 256] to verify that there was no hemorrhage in
any of these mice.
hADMSC Collection
Adipose tissue was harvested from the subcutaneous abdominal
adipose tissue by lipo-aspiration from one young healthy female
then transferred to the cell therapy unit for digestion. Negativity
of the donor for HIV1/2, HBV, HCV, HTLV1/2, HSV1/2,
Syphilis, CMV, and EBV serology was verified in order to
be compliant with the Directive 2006/17/EC. At the end of
the aspiration procedure, adipose tissue was transferred to
the Etablissement Français du Sang (EFS) cell therapy unit
for digestion according to an internal procedure. The adipose
tissue stem cell line RESSTORE01 (Master Cell Bank/Stock
no. 1—Donor RESSSTORE01, Batch no. 591133643763) was
cultured in the growth medium Alpha MEM (Macopharma)
supplemented with 5% human platelet lysate (Stemulate, Cook
Medical, United States). The medium was changed twice
each week and cells were passaged when they reached (85%)
confluence. The cells were detached with TrypLE Select (Life
Technologies) for 7–10 min. The RESSTORE01 cell phenotype
was analyzed with flow cytometry (FACS Canto II, BD
Biosciences) at passage P1. The BD Stemflow hMSC Analysis
kit (ref: 562245, Becton Dickinson) was used to phenotype the
ADSC that were characterized by the expression of the surface
markers CD73, CD44, CD105, and CD90. In addition, in order to
identify non-mesenchymal cell contamination, specific markers
of monocytes/macrophages (CD11b), lymphocytes (CD19), pan-
leucocytes (CD45), hematopoietic stem cells (CD34), and
HLA-DR were performed. The expression of these positive
markers should be ≥90% and ≤5% for the negative markers.
These specifications have been established based on the
recommendations of the International Society for Cellular
Therapy. These hADMSC were harvested after expansion in
MEMα medium (Thermofisher) and human platelet lysate 5%
(Cook Regentec). At D2 post-stroke 500,000 cells in 0.2 mL PBS
were administered through the retroorbital vein.
Sensorimotor Deficit Assessment
Mice underwent a neurological evaluation consisting of five tests:
neurological score, grip and string test, beam walking test and
pole test, currently used in our laboratory (Poittevin et al., 2013,
2015; Hilal et al., 2018) and that have been fully described
elsewhere (Frechou et al., 2019). The maximum global score was
19, with the lower neurologic score corresponding to a more
severe deficit. The assessment was performed at D-1 (habituation
stage, the mouse being its own control), D2 (just before cell
infusion), D3, D7, D9, and D14 in all groups.
Cognitive Assessment
Before testing spatial memory (Barnes maze), we evaluated the
sensorimotor deficit as well as spontaneous locomotor activity
(open field) at D28, since residual neurological sensorimotor
deficit or anxiety could otherwise introduce a bias in the
interpretation of the Barnes maze. Cognitive assessment was
performed in a dedicated room where mice were placed 2 weeks
before in order to acclimate to the room where they were
subjected to a 12 h night-day cycle with food and water
provided ad libitum.
Open Field
Residual sensorimotor deficit and potential anxiety likely to
cause the mice to “freeze,” could interfere with the Barnes maze
evaluation thus skewing the results. We used the open-field
as previously described (Cifuentes et al., 2015). Spontaneous
activity (distance traveled in cm and mean velocity in cm/s)
was measured automatically for 30 min by an EthoVision XT
system and analyzed by EthoVision XT 11.5 tracking software
(Noldus, Wageningen, Netherlands). Open field activity was
assessed at D28 in all groups that were then tested on the
Barnes Maze platform.
Barnes Maze
The Barnes maze is an open space 1 m in diameter, consisting
of 20 holes spaced equidistantly around the circumference; one
escape box is placed under one of the holes that the mouse will
learn to find using visual cues placed in the behavior room. Mice
are trained three times a day with a 15-min rest between each trial
and recorded with a camera.
As previously described (Cifuentes et al., 2017), at D30, the
mouse has to learn the location of the escape box on four
consecutive days, named the training phase (1st day to 4th day
of evaluation). After 2 days of resting (7th day of evaluation),
mice are tested on their ability to recall the place of the escape
box, named the retention phase. The next day (8th day), the
escape is box is changed from its original location and mice have
to adapt, learn and memorize the new location during 2 days
(8th day and 9th day). During this last phase or reversal phase,
brain plasticity is evaluated. During each phase, the latency to
escape (seconds) is measured.
Assessment of Infarct Volume
At D9, 1 week after hADMSC IV administration, mice were
transcardiacally perfused with heparinized saline, followed by
4% paraformaldehyde (PFA). Brain was removed, post-fixed
overnight in PFA and cryoprotected in 20% sucrose. Coronal
30 µm-thick sections were cut frozen using a cryostat CM 1950
(Leica Biosystems, Nußloch, Germany). Every eight 30 µm-
thick floating section was stained with Cresyl violet. Using
ImageJ software (National Institutes of Health, Bethesda, MD,
United States), the cortical infarct area was measured to
calculate the stroke volume (mm3) by integrating measured
areas and distances between sections. Measured infarct volume
was corrected for edema with the following formula: corrected
infarct volume = measured infarct volume × (contralateral
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hemisphere volume/ipsilateral hemisphere volume) as already
described (Poittevin et al., 2013).
Assessment of Histological
Response to hADMSC
Thirty µm-thick coronal floating sections were incubated
with primary antibody overnight at 4◦C to detect neuroblasts
using anti-doublecortin (DCX) (1:4000, Abcam, Cambridge,
United Kingdom); microglial cells using anti-Iba1 (1:200, Wako,
Japan), T-lymphocytes using anti-CD3 (1/200, Dako, Santa Clara,
United States), astrocytes using anti-GFAP (1:200, Millipore,
Burlington, MA, United States) and vessels using the anti-
glucose transporter-1 (Glut-1) (1:500, Millipore, Burlington, MA,
United States). Appropriate fluorescent-labeled secondary alexa
fluor 594 or 488 antibodies (Molecular Probes, Eugene, OR,
United States 1:400) were applied for 1 h at room temperature.
Specificity was checked by omitting the primary antibody. As
doublecortin is expressed in newborn and migrating neurons,
we assumed that DCX+ cells reflect neurogenesis (Brown et al.,
2003; Jin et al., 2010).
Morphological Analysis
Cells density assessments were conducted blindly (vascular risk
factor and treatment) at D9 and D40 and performed on three
coronal brain sections at +0.80, −0.80, and −1.20 mm relative
to bregma, that consistently contained the infarct area.
Neuroblasts density was assessed by calculating the DCX-
positive area (X10) using NIH ImageJ software, in the whole
ipsilateral hemisphere to stroke, actually only found in the
subventricular zone and along the corpus callosum along which
they migrate toward the lesion.
Microglial/macrophage density was assessed by calculating the
Iba1-positive area (X5) using NIH ImageJ software in the peri-
infarct area.
T-cell density was manually assessed by counting CD3+ cells
in each section, actually only present in the infarct area, and
expressed as the number of CD3+ cells per section.
Astrocytes density was assessed by calculating the GFAP-
positive area in 2 R.O.I (X40) using NIH ImageJ software in the
peri-infarct area.
Vessel density was assessed by calculating the GLUT-1-positive
area (X20) using NIH ImageJ software in the peri-infarct area.
All calculated areas were expressed as arbitrary units.
Statistical Analysis
Statistical analyses were performed using Prism 7.02 software
(GraphPad, San Diego, CA, United States). The data are
expressed in mean ± SD. The Shapiro–Wilk normality test was
used to assess whether the data corresponded to a Gaussian
distribution. Comparisons between the four groups of diabetic
mice or of hypertensive mice were analyzed using either
ANOVA or a Kruskal–Wallis test. Two-way ANOVA for repeated
measures was used to analyze data of the training (1st to 4th days)
and reversal (8th to 9th days) phases in the Barnes maze. Post hoc
analyses were performed using Bonferroni’s multiple comparison
tests. A value of p< 0.05 was considered statistically significant.
RESULTS
Mean glycemia was not significantly different at D-1
between D-PBS (451.7 ± 59.7 mg/dl) and D-hADMSC mice
(431.8 ± 50.1 mg/dl). No mice died whatever the group during
surgery and during follow-up. hADMSC did not significantly
modify glycemia in diabetic mice during follow-up until D40
(460.3 ± 56.6 mg/dl) compared to untreated D-PBS mice
(493.3± 70.9 mg/dl) (n = 13–14).
Before stroke, systolic and diastolic blood pressure were
significantly higher in HT mice (134.9 ± 5.9/89.0 ± 7.2 mmHg)
compared to NHT mice (114.0 ± 7.0/78.6 ± 6.2 mmHg)
(p < 0.0001). After stroke and during follow-up, hADMSC
did not significantly modify systolic blood pressure (NHT-PBS:
104.9± 14.1 mmHg vs. NHT-hADMSC 111.7± 6.3 mmHg; HT-
PBS: 138.3± 7.2 mmHg vs. HT-hADMSC: 136.2± 11.2 mmHg),
or diastolic blood pressure (NHT-PBS: 82.1 ± 9.5 mmHg vs.
NHT-hADMSC: 80.9 ± 6.5 mmHg; HT-PBS: 86.3 ± 7.3 mmHg
vs. HT-hADMSC: 90.1 ± 6.6 mmHg). Heart rate (beats per min)
did not differ significantly between groups (NHT-PBS: 536 ± 10
vs. NHT-hADMSC: 522 ± 17 vs. HT-PBS: 518 ± 36 vs. HT-
hADMSC 507 ± 35) (n = 18–20). No mice died whatever the
group during surgery and during follow-up.
Doppler Imaging of Cerebral
Vasoreactivity to Inhaled CO2
Cerebral vasoreactivity was assessed 8 weeks after the induction
of chronic hyperglycemia or chronic hypertension, before
cerebral ischemic induction. Mean blood flow velocities at the
basilar trunk were not significantly modified after CO2 inhalation
in diabetic mice (air: 12.0 ± 1.7 versus CO2: 11.0 ± 1.4 cm/s)
(n = 7) and in hypertensive mice (air: 15.7 ± 2.2 versus CO2:
15.8 ± 2.6 cm/s) (n = 14), whereas they were significantly
increased when compared to the same control mice (non-
diabetic and non-hypertensive mice) (air: 15.4± 2.4 versus CO2:
17.7 ± 2.2 cm/s, p = 0.0001) (n = 9), indicating that in this last
group only, CO2 induced arteriolar vasodilation.
Sensorimotor Deficit
At D2, compared to D-1, we observed a significant reduction
in the neurological score in diabetic and hypertensive mice
compared to control non-diabetic and non-hypertensive mice,
indicating that both diabetes and hypertension induced a more
severe sensorimotor deficit compared to mice that were subjected
to the same pMCAo stroke model but without vascular risk
factor. From D2 to D9, this deficit significantly persisted over
time until complete recovery by D14, except in D-PBS that had
nevertheless completely recovered by D28. However, whatever
the time of evaluation, there was no significant difference in the
neurological score between untreated and treated mice whatever
the risk factor, indicating that hADMSC had no effect on
sensorimotor recovery (Figures 2A,B and Tables 1, 2).
Open Field
The ability of mice to spontaneously walk the equivalent
distance with similar velocity was verified in the open field,
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FIGURE 2 | Assessment of sensorimotor deficit between D-1 and D14 and of spontaneous locomotor activity measured at D28 in ND-PBS, untreated non-diabetic
mice; ND-hADMSC, treated non-diabetic mice; D-PBS, untreated diabetic mice and D-hADMSC, treated diabetic mice (n = 13–20) (A) and NHT-PBS, untreated
non-hypertensive mice; NHT-hADMSC, treated non-hypertensive mice; HT-PBS, untreated hypertensive mice and HT-hADMSC, treated hypertensive mice
(n = 8–20) (B). Diabetic and hypertensive mice showed a more severe sensorimotor deficit than control mice during the whole evaluation until they fully recovered at
D14 except D-PBS mice (p < 0.01 versus ND-PBS and p < 0.01 versus ND-hADMSC). No differences were evidenced between untreated and treated mice. At
D28, no differences were evidenced between mice in the total distance traveled or mean velocity at open field; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗∗p < 0.0001 between
ND-PBS versus D-PBS mice and NHT-PBS versus HT-PBS mice; #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 between ND-PBS versus D-hADMSC and
between NHT-PBS versus HT-hADMSC; §p < 0.05, §§p < 0.01, §§§p < 0.001, §§§§p < 0.0001 between ND-hADMSC versus D-PBS and between NHT-hADMSC
versus HT-PBS; $p < 0.05, $$p < 0.01, $$$$p < 0.0001 between ND-hADMSC versus D-hADMSC and NHT-hADMSC versus HT-hADMSC.
before the Barnes Maze evaluation. Indeed, any residual motor
impairment could skew the interpretation of spatial long-term
memory. No differences were observed between mice in the
distance traveled or mean velocity in the diabetic groups or
in the hypertensive groups, whether the mice were treated or
untreated (Figures 2A,B).
Barnes Maze
In the training phase, D-hADMSC had an impaired learning
ability at the 2nd and 3rd day compared to ND-PBS (p < 0.01
TABLE 1 | Sensorimotor assessment in diabetic mice.
Day ND-PBS ND-hADMSC D-PBS D-hADMSC
(n = 20) (n = 16) (n = 14) (n = 13)
D-1 18.85 ± 0.67 18.94 ± 0.25 19.00 ± 0.00 18.92 ± 0.28
D2 18.35 ± 1.14 18.56 ± 0.96 13.29 ± 2.13 13.69 ± 2.14
D3 18.00 ± 1.41 18.06 ± 1.29 14.64 ± 2.41 13.77 ± 2.59
D7 18.40 ± 1.08 19.00 ± 0.00 14.50 ± 1.31 15.17 ± 2.38
D9 18.40 ± 1.23 18.69 ± 0.87 15.50 ± 2.38 16.23 ± 2.048
D14 18.90 ± 0.32 19.00 ± 0.00 17.50 ± 1.38 18.43 ± 0.79
Control diabetic (D-PBS) and non-diabetic (ND-PBS) mice, treated diabetic
(D-hADMSC), and non-diabetic mice (ND-hADMSC).
and p < 0.001, respectively). At the 3rd day, D-PBS also
presented an impairment compared to ND-PBS (p < 0.05)
and D-hADMSC compared to ND-hADMSC (p < 0.01).
However, all mice learned the same on the 4th day. In the
retention phase, only diabetic mice without treatment showed
a delayed latency to escape reflecting an impaired long-term
memory ability (ND-PBS versus D-PBS, p< 0.001). D-hADMSC
did not show differences compared to non-diabetic mice,
nor with D-PBS mice. On the reversal phase, all diabetic
mice had an impaired cerebral plasticity compared to non-
diabetic mice (ND-PBS versus D-PBS, p < 0.01; ND-PBS
TABLE 2 | Sensorimotor assessment in hypertensive mice.
Days NHT-PBS NHT-hADMSC HT-PBS HT-hADMSC
(n = 8) (n = 10) (n = 20) (n = 18)
D-1 19.00 ± 0,00 18.89 ± 0.33 19.00 ± 0.00 19.00 ± 0.00
D2 18.25 ± 0.89 17.44 ± 1.24 14.15 ± 3.41 14.17 ± 3.55
D3 18.50 ± 0.93 18.60 ± 0.52 14.25 ± 3,82 15.28 ± 3.16
D7 19.00 ± 0.00 19.00 ± 0.00 14.65 ± 4.27 16.00 ± 2.89
D9 19.00 ± 0.00 19.00 ± 0.00 16.25 ± 3.19 15.50 ± 4.32
Control hypertensive (HT-PBS) and non-hypertensive mice (NHT-PBS) and treated
hypertensive (HT-hADMSC) and non-hypertensive mice (NHT-hADMSC).
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FIGURE 3 | Assessment of long-term spatial memory between D30 and D38 in ND-PBS, untreated non-diabetic mice; ND-hADMSC, treated non-diabetic mice;
D-PBS, untreated diabetic mice and D-hADMSC, treated diabetic mice (n = 9–16) (A) and NHT-PBS, untreated non-hypertensive mice; NHT-hADMSC, treated
non-hypertensive mice; HT-PBS, untreated hypertensive mice and HT-hADMSC, treated hypertensive mice (n = 8–10) (B). hADMSC did not significantly modify the
latency to escape of pMCAo mice whatever the risk factor; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ND-PBS versus D-PBS; #p < 0.05, ##p < 0.01, ###p < 0.001,
####p < 0.0001 ND-PBS versus D-hADMSC; §p < 0.05, §§p < 0.01, §§§p < 0.001, §§§§p < 0.0001 ND-hADMSC versus D-PBS; $p < 0.05, $$p < 0.01,
$$$p < 0.001, $$$$p < 0.0001 ND-hADMSC versus D-hADMSC.
versus D-hADMSC, p < 0.01; ND-hADMSC versus D-PBS,
p < 0.01; ND-hADMSC versus D-hADMSC, p < 0.05). This
impairment was also present on the 9th day for D-PBS mice
and D-hADMSC compared to ND-PBS mice (p < 0.05)
(Figure 3A and Table 3).
To summarize, hADMSC injected intravenously 2 days after
a focal cerebral ischemia failed to protect from post-stroke
cognitive impairment in diabetic mice.
In hypertensive mice, we evidenced no differences in the
training phase, the retention phase or the reversal phase between
the four groups, indicating that 16 weeks of hypertension did
not induce a worse post-stroke cognitive impairment compared
TABLE 3 | Barnes maze in diabetic mice.
Days ND-PBS ND-hADMSC D-PBS D-hADMSC
(n = 16) (n = 13) (n = 10) (n = 9)
1st 157.80 ± 53.71 146.00 ± 59.73 181.20 ± 35.50 194.00 ± 60.40
2nd 64.60 ± 28.10 88.63 ± 44.34 110.50 ± 27.29 128.90 ± 65.16
3rd 48.35 ± 20.47 56.46 ± 42.37 101.00 ± 33.31 119.90 ± 70.87
4th 35.26 ± 20.97 52.70 ± 40.81 81.38 ± 30.90 70.76 ± 48.27
7th 23.23 ± 9.85 38.29 ± 35.77 71.80 ± 50.08 53.02 ± 41.96
8th 59.09 ± 25.23 61.35 ± 30.93 107.90 ± 41.58 105.30 ± 44.89
9th 31.53 ± 12.80 32.13 ± 17.95 72.71 ± 32.68 57.20 ± 43.07
Control diabetic (D-PBS) and non-diabetic (ND-PBS) mice, treated diabetic
(D-hADMSC), and non-diabetic mice (ND-hADMSC).
to non-hypertensive mice subjected to a focal cerebral ischemia.
As we have previously shown (Mangin et al., 2019) that pMCAo
mice, without vascular risk factor, does not have significantly
modified scores at Barnes Maze, our results would indicate that
our model did not produce cognitive impairment in hypertensive
mice. The effect of hADSMC could therefore not be evaluated
(Figure 3B and Table 4).
Infarct Volume
Infarct volume was not significantly modified at day 9 in the
diabetic groups or in the hypertensive groups, whether the mice
were treated or untreated (Figure 4).
TABLE 4 | Barnes maze in hypertensive mice.
Days NHT-PBS NHT-hADMSC HT-PBS HT-hADMSC
(n = 9) (n = 10) (n = 10) (n = 8)
1st 170.20 ± 40.06 135.80 ± 53.44 159.60 ± 50.13 137.40 ± 31.63
2nd 79.38 ± 40.17 74.10 ± 40.59 88.22 ± 54.67 80.18 ± 42.32
3rd 69.61 ± 51.14 46.22 ± 26.37 70.14 ± 43.29 54.19 ± 44.01
4th 33.09 ± 19.45 23.67 ± 12.43 52.63 ± 37.05 30.92 ± 12.06
7th 20.60 ± 3.76 24.46 ± 9.08 27.13 ± 14.28 38.32 ± 29.13
8th 51.53 ± 19.76 49.45 ± 24.09 56.59 ± 29.37 56.67 ± 34.05
9th 35.75 ± 17.88 27.12 ± 14.78 33.20 ± 14.60 34.47 ± 16.90
Control hypertensive (HT-PBS) and non-hypertensive mice (NHT-PBS) and treated
hypertensive (HT-hADMSC), and non-hypertensive mice (NHT-hADMSC).
Frontiers in Neuroscience | www.frontiersin.org 7 July 2019 | Volume 13 | Article 718
fnins-13-00718 July 12, 2019 Time: 15:36 # 8
Mangin et al. IV hADMSC in Stroke Mice Inter Comorbidity
FIGURE 4 | Assessment of infarct volume at D9 in ND-PBS, untreated non-diabetic mice; ND-hADMSC, treated non-diabetic mice; D-PBS, untreated diabetic mice
and D-hADMSC, treated diabetic mice (n = 6–10) (A) and NHT-PBS, untreated non-hypertensive mice; NHT-hADMSC, treated non-hypertensive mice; HT-PBS,
untreated hypertensive mice and HT-hADMSC, treated hypertensive mice (n = 7–10) (B). hADMSC did not significantly reduce infarct volume whatever the risk factor.
Representative crésyl violet sections of infarct areas for non-diabetic, diabetic, non-hypertensive, and hypertensive mice (C).
Neurogenesis, Microglial/Macrophages,
T Lymphocytes, Astrocytes, and Vessel
Density and Were Not Significantly
Modified by hADMSC in Diabetic and
Hypertensive Mice
Neurogenesis
Comparison of the DCX-positive area was performed in order
to assess neurogenesis between groups. At D9, no differences
were evidenced between untreated and treated non-diabetic
and diabetic mice and between untreated and treated non-
hypertensive and hypertensive mice.
At D40, there was an overall ANOVA significance between
untreated and treated non-diabetic and diabetic mice (p < 0.01).
The DCX-positive area was significantly increased in
D-hADMSC mice (1.6 ± 0.28 mm3) compared to ND-PBS
mice (0.42 ± 0.40 mm3) (p < 0.001), whereas there was no
significant difference with the other groups (1.01 ± 0.51 mm3,
ND-hADMSC mice; 1.14 ± 0.57 mm3, D-PBS mice). No
differences were evidenced between untreated and treated
non-hypertensive and hypertensive mice.
Between D9 and D40, there was a significant reduction in
neuroblasts density in ND-PBS (p < 0.001), ND-hADMSC
(p < 0.05), D-PBS (p < 0.05) and D-hADMSC mice (p < 0.05),
and in NHT-PBS (p< 0.05) and NHT-hADMSC mice (p< 0.01);
no differences were observed in HT-PBS and HT-hADMSC mice
over time (Figure 5).
Microglial/Macrophages Density
Comparison of the Iba1-positive area was performed in
order to assess microglial/macrophages density between groups.
Microglia/macrophage cells (Iba1+) adopted a round amoeboid
shape in the peri-infarct area, indicating a change in the
state of activation. At D9, no differences were evidenced
between untreated and treated non-diabetic and diabetic
mice or between untreated and treated non-hypertensive and
hypertensive mice (Figure 6).
At D40, rare microglial/macrophages were evidenced on
sections, and therefore no quantification was performed.
T Lymphocytes Density
Comparison of CD3+ cells density was performed in order
to assess T lymphocytes density between groups. At D9, no
differences were evidenced between untreated and treated non-
diabetic and diabetic mice or between untreated or treated non-
hypertensive or hypertensive mice.
At D40, no differences were evidenced between untreated and
treated non-diabetic and diabetic mice or between untreated or
treated non-hypertensive or hypertensive mice.
Between D40 and D9, there was a significant increase in
CD3+ cells density in D-PBS mice (84.3 ± 58/section versus
40.6 ± 15.0/section) (p < 0.05) only, whereas there were no
significant differences in the CD3+ cells density between treated
diabetic mice and untreated or treated non-diabetic mice. No
differences were observed between untreated or treated non-
hypertensive or hypertensive mice overtime (Figure 7).
Astrocytes Density
Comparison of the GFAP-positive area was performed in order
to assess astrocytes density between groups. Activated astrocytes
only were considered, when they adopted a narrow cell body
and thickened their branches. At D9, no differences were
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FIGURE 5 | Assessment of neuroblasts density at D9 and D40 in ND-PBS, untreated non-diabetic mice; ND-hADMSC, treated non-diabetic mice; D-PBS, untreated
diabetic mice and D-hADMSC, treated diabetic mice (D9: n = 6–10, D40: n = 5–9) (A) and NHT-PBS, untreated non-hypertensive mice; NHT-hADMSC, treated
non-hypertensive mice; HT-PBS, untreated hypertensive mice and HT-hADMSC, treated hypertensive mice (D9: n = 7–8, D40: n = 7–10) (B). hADMSC did not
significantly increase neuroblasts density except at D40 in D-hADMSC mice compared to ND-PBS mice. Between D9 and D40, a significant decrease in neuroblasts
density was evidenced in ND-PBS, p < 0.001; ND-hADMSC, p < 0.05; D-PBS, p < 0.05; D-hADMSC, p < 0.05) and in NHT-PBS (p < 0.05) and NHT-hADMSC
(p < 0.01). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. DCX immunostaining in the SVZ of untreated diabetic mice, at D9 and at D40, scale bar: 50 µm; C, cortex;
V, ventricle; SVZ, subventricular zone; red square, region of interest (C).
evidenced between untreated and treated non-diabetic and
diabetic mice. There was an overall significant difference between
untreated or treated non-hypertensive or hypertensive mice
(p = 0.02) and the GFAP-positive area was significantly decreased
in HT-PBS (2.59 ± 0.35 A.U.) compared to NHT-PBS mice
(8.06± 4.58 A.U.) (p< 0.05). No differences were evidenced with
the other groups.
At D40, no differences were evidenced between untreated
and treated non-diabetic and diabetic mice. There was an
overall significant difference between untreated or treated non-
hypertensive or hypertensive mice (p = 0.015) and the GFAP-
positive area was significantly increased in HT-hADMSC mice
(12.07 ± 2.43 A.U.) versus NHT-PBS mice (5.22 ± 4.52
A.U.) (p < 0.05), whereas no differences were evidenced with
the other groups.
Between D40 and D9, the GFAP-positive area was significantly
reduced in ND-PBS (2.04 ± 0.94 A.U. versus 10.90 ± 4.01
A.U.) (p < 0.0001), ND-hADMSC (2.79 ± 1.85 A.U. versus
9.72 ± 5.95 A.U.) (p < 0.05), D-PBS (2.34 ± 1.56 A.U. versus
10.49 ± 2.87 A.U.) (p < 0.01), and D-hADMSC (4.26 ± 1.74
A.U. versus 8.15 ± 0.80 A.U.) (p < 0.01) mice. By contrast, the
GFAP-positive area was significantly increased in HT-PBS mice
(13.47 ± 4.34 A.U. versus 2.59 ± 0.35 A.U.) (p < 0.01) and
HT-hADMSC mice (12.07 ± 2.43 A.U. versus 5.49 ± 2.31 A.U.)
(p< 0.001) (Figure 8).
Vessel Density
Comparison of the GLUT-1-positive area was performed in
order to assess vessel density between groups. At D9 or at D40,
no differences were evidenced between untreated and treated
non-diabetic and diabetic mice or between untreated or treated
non-hypertensive or hypertensive mice.
Between D9 and D40, no differences in the GLUT-1-
positive area were evidenced between untreated and treated
non-diabetic and diabetic mice or between untreated or treated
non-hypertensive or hypertensive mice (Figure 9).
DISCUSSION
We showed that IV administration of hADMSC 2 days after focal
cerebral ischemia induction did not significantly modify infarct
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FIGURE 6 | Assessment of Iba1+ cell density at D9 in ND-PBS, untreated non-diabetic mice; ND-hADMSC, treated non-diabetic mice; D-PBS, untreated diabetic
mice and D-hADMSC, treated diabetic mice (n = 5–9) (A) and NHT-PBS, untreated non-hypertensive mice; NHT-hADMSC, treated non-hypertensive mice; HT-PBS,
untreated hypertensive mice and HT-hADMSC, treated hypertensive mice (n = 6–9) (B). No significant reduction in microglia/macrophages density by hADMSC was
evidenced whatever the risk factor. Iba1 immunostaining in D-PBS mice with magnification showing amoeboid cells, scale bar: 50 µm; C, cortex; V, ventricle; SVZ,
subventricular zone; red circle: region of interest (C).
volume, short and long-term functional outcome in diabetic
or hypertensive mice neither was associated with significant
modification of neurogenesis, inflammatory cells density or
angiogenesis, whatever the analysis time frame.
Most of preclinical studies investigating the beneficial effect of
cell therapy have been performed in healthy young male rodents,
even when vascular risk factors are known to worsen the infarct
lesion, functional outcome and mortality, and therefore question
the efficiency of cell therapy. We have used a diabetic stroke
model that we previously characterized (Poittevin et al., 2015).
Streptozotocin induced chronic hyperglycemia was associated
after 8 weeks to impaired vasoreactivity and decreased brain
eNOS and nNOS expression. After stroke induction, diabetic
mice had an increased sensori-motor disability (Poittevin
et al., 2015) and presented cognitive impairment at D30
compared to non-diabetic mice (Mangin et al., 2019). For the
hypertensive model, we used L-NAME in daily drinking water
that induced chronic mild hypertension, rather than chronic
infusion of angiotensin 2 that is responsible for a more severe
hypertension and requires additional surgery for angiotensin 2
pump implantation (Cifuentes et al., 2015, 2017). This model
was also associated with impaired vasoreactivity after 8 weeks,
but to achieve a sensori-motor impairment in our experimental
conditions, we had to administer L-NAME during 16 weeks.
Cell therapy in post-stroke diabetic rodents has already been
investigated using various cell types, sources and administration
pathways. Allogenic bone-marrow derived MSC (BM-MSC)
from healthy rats have been intravenously injected 1 day after
stroke in type 1 diabetic rats, and 3 days after stroke in
type 2 diabetic rats subjected to tMCAo. In the first case,
blood-brain-barrier permeability and mortality were increased
with an opposite outcome in the second case (Chen et al.,
2011; Ding et al., 2016). In type 2 diabetic rats, xenogenic
human BM-MSC that were IV delivered 3 days after a tMCAo,
significantly improved neurological function without affecting
infarct volume. Endothelial progenitor cells (EPCs) isolated from
human umbilical cord blood and IV delivered immediately after
reperfusion in type 1 diabetic mice subjected to a tMCAo,
reduced blood-brain barrier leakage, reduced infarct volume
and attenuated neurological impairment (Geng et al., 2017). By
contrast, intraarterial delivery of allogenic BM-EPC in type 2
diabetic mice, 24 h after induction of a photothrombotic stroke,
failed to significantly improve behavioral scores and infarct
volume (Bai et al., 2015). Diabetes models, stroke models, species,
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FIGURE 7 | Assessment of CD3+ cells density at D9 and D40 in ND-PBS, untreated non-diabetic mice; ND-hADMSC, treated non-diabetic mice; D-PBS, untreated
diabetic mice and D-hADMSC, treated diabetic mice (D9: n = 5–6, D40: n = 5–7) (A) and NHT-PBS, untreated non-hypertensive mice; NHT-hADMSC, treated
non-hypertensive mice; HT-PBS, untreated hypertensive mice and HT-hADMSC, treated hypertensive mice (D9: n = 5–7, D40: n = 5) (B). hADMSC did not
significantly modify the T-lymphocytes density whatever the risk factor. Between D9 and D40, there was a significant increase in T-lymphocytes density in D-PBS
mice (∗p < 0.05). From left to right, DAPI, CD3 and merge immunostaining, scale bar: 20 µm; C, cortex; V, ventricle; SVZ, subventricular zone (C).
delay of injection after stroke and allograft versus xenograft
differed between studies and with ours, precluding direct
comparison. Interestingly, xenograft or delayed injection of BM-
MSC, up to 3 days, in diabetic animals, was not an impediment
to improved outcome. Cell therapy in hypertensive rodents have
only been investigated in spontaneously hypertensive rats. BM-
derived mononuclear cells did not succeed in demonstrating
sensori-motor improvement when IV transplanted 1 h after
induction of a photothrombotic stroke (Diederich et al., 2014)
or IV transplanted 3 h after reperfusion in a tMCAo stroke
model (Minnerup et al., 2014), nor did umbilical cord blood
mononuclear cells (Weise et al., 2014). Only maternal placenta
derived MSC that were intravenously administered, led to an
improvement of functional outcome (Kranz et al., 2010). These
mitigate results underline the necessity to integrate co-morbidity
factors into stroke models.
The source of MSC may matter. Adipose tissue is an
interesting alternative donor tissue to bone marrow. Lipoas-
piration allows easy collection of great quantities of cells
(Mangin and Kubis, 2018). In addition, and in a translational
point of view, ADMSC have a low immunogenicity profile
enabling allogeneic administration with good tolerance. When
transplanted in a tMCAo model, allogenic ADMSC IV delivered
soon after reperfusion, showed a remarkable attenuation of
ischemic damage compared to BM-MSC treated mice (Ikegame
et al., 2011). In rats, a beneficial effect of ADMSC was observed
whatever the IV (Gutierrez-Fernandez et al., 2015) or IA
(Huang et al., 2017) administration, in a pMCAo and
tMCAo model, respectively. Interestingly, xenogeneic ADMSC
or allogeneic ADMSC showed equal efficacy in terms of
functional recovery and decreased ischemic brain damage when
IV delivered 30 min after pMCAo (Gutierrez-Fernandez et al.,
2015). To summarize, ADMSC seem to be more promising than
BM-MSC, the xenograft and allograft are of equal efficacy, they
have been constantly reported to improve functional outcome in
rats and mice, the tMCAo stroke model being the most widely
used. However, none of these animals had associated vascular risk
factors and cells were constantly administered, within 24 h after
cerebral ischemia induction, both conditions that might explain
our negative results.
Our model is not questioned since, using the same pMCAo
model in diabetic mice, we previously showed a dramatic
functional improvement and a reduced infarct volume following
treatment with the immunomodulatory drug glatiramer acetate
(Mangin et al., 2019), with peripheral blood mononuclear cells
pretreated with ephrin-B2 in diabetic (personal unpublished
data) but also in non-diabetic mice (Hilal et al., 2018). In
literature, cell therapy is mainly reported in tMCAo stroke
models. However, the pMCAo model offers many advantages.
The tMCAO stroke model in diabetic mice is associated with a
high mortality after 7 days which prevents any further follow-up
(Poittevin et al., 2015). We had previously shown that diabetic
mice developed post-stroke dementia after pMCAo (Mangin
et al., 2019), which was one of the functional outcomes we
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FIGURE 8 | Assessment of GFAP+ cells density at D9 and D40 in ND-PBS, untreated non-diabetic mice; ND-hADMSC, treated non-diabetic mice; D-PBS,
untreated diabetic mice and D-hADMSC, treated diabetic mice (D9: n = 5–10, D40: n = 5–11) (A) and NHT-PBS, untreated non-hypertensive mice; NHT-hADMSC,
treated non-hypertensive mice; HT-PBS, untreated hypertensive mice and HT-hADMSC, treated hypertensive mice (D9: n = 7–9, D40: n = 6–11) (B). hADMSC did
not significantly modify the astrocytes density whatever the risk factor. Between D9 and D40, there was a significant reduction in activated astrocytes in ND-PBS,
ND-hADMSC, D-PBS, and D-hADMSC mice and a significant increase in activated astrocytes in HT-PBS and HT-hADMSC mice; ∗p < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. GFAP immunostaining, scale bar: 50 µm; C, cortex; V, ventricle; SVZ, subventricular zone; green squares: regions of interest (C).
wanted to explore. The smaller infarct, restricted to the cortex
was crucial in our model, because we did want to spare the
hippocampus from the neuronal damage. Moreover, it was
recently reported that even a minor stroke increases the incidence
of post-stroke dementia and that diabetes is the only vascular risk
factor identified (Pendlebury et al., 2019). Although the infarct
is smaller in this pMCAo stroke model compared to the tMCAo
model in mice, brain inflammation is exacerbated (Zhou et al.,
2013) and even more in diabetic mice (Mangin et al., 2019)
and in hypertensive rats (Moller et al., 2015). This is important
to consider since the efficiency of hADMSC is related to their
“immunomodulatory properties” (Leu et al., 2010; Melief et al.,
2013). At last, “healthy” non-diabetic and non-hypertensive mice
subjected to a pMCAo presented little sensorimotor deficit that
recovered completely very quickly and prevented us to evaluate
any effect of cells in those mice, but this was not the primary
endpoint of our study.
We cannot rule out that a different culture procedure might
have led to different results. The fact that hADMSC were collected
from only one donor might question the efficiency of these
cells. However, using the cells of the same donor, Mu et al.
(2019) succeeded in demonstrating functional improvement in
treated non-diabetic adult male Sprague Dawley rats, subjected to
focal cerebral ischemia, and using the sticky label test. However,
this does not exclude that there might be variability in the
response that should be tested by comparing the efficiency of
these cells between various donors. Also, the delay of injection
might have been too late. In our previous cell therapy studies
in pMCAO mice, we constantly IV transplanted the cells within
the first 24 h after stroke induction (Nih et al., 2012; Hilal
et al., 2018) and a beneficial effect was observed when ADMSC
were IV (Gutierrez-Fernandez et al., 2015) or IA administered
(Huang et al., 2017), 30 min and 24 h respectively after the
cerebral ischemia induction. The 48 h delay was chosen in
that particular study to get along with the parallel clinical trial
that aimed to widen the therapeutic window and because mice
were randomized according to the infarct volume determined at
cerebral MRI the day before.
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FIGURE 9 | Assessment of GLUT-1+ cells area at D9 and D40 in ND-PBS, untreated non-diabetic mice; ND-hADMSC, treated non-diabetic mice; D-PBS, untreated
diabetic mice; and D-hADMSC, treated diabetic mice (D9: n = 5–11, D40: n = 5–9) (A) and NHT-PBS, untreated non-hypertensive mice; NHT-hADMSC, treated
non-hypertensive mice; HT-PBS, untreated hypertensive mice and HT-hADMSC, treated hypertensive mice (D9: n = 7–10, D40: n = 8–9) (B). Vessel density was not
significantly modified over time and hADMSC did not significantly modify the vessels density whatever the risk factor. GLUT-1 immunostaining, scale bar: 100 µm;
C, cortex; V, ventricle; SVZ, subventricular zone; green squares: regions of interest (C).
The discrepancies of our results between mice and those
obtained in rats by the other teams of the RESSTORE project
(Mu et al., 2019), could be related to species differences in
the immune system. In an in vitro model of oxygen-glucose
deprivation on primary cultures of neurons, astrocytes, microglia
in rats, mice or humans, the cytokines levels were differently
expressed between all three species (Du et al., 2017), or even
may be present in one species and not in the other (Mestas
and Hughes, 2004). MSC have been shown to secrete cytokines
and growth factors that inhibit T cells proliferation, decrease
TNFα secreted by dendritic cells (Uccelli et al., 2008) and at
the same time polarize lymphocytes and microglial cells to an
“anti-inflammatory” and beneficial phenotype (Ankrum et al.,
2014). Although hADMSC have been reported to have a higher
immunomodulatory capacity than BM-derived counterparts,
including increase of IL-6 and TGF-β1 (Melief et al., 2013)
and decrease of IL-18 (Leu et al., 2010), we did not evidence
any modification of microglial/macrophages, T lymphocytes,
or astrocytes densities between treated and untreated mice,
when adding co-morbidity, but we did not measure brain
cytokines levels. We cannot exclude either a participation of
peripheral immune organs and modification of blood immune
cells and cytokines release to stroke response and to comorbid
factors. Indeed, spleen and systemic immune response have
shown contribution to the pathophysiology of stroke (Offner
et al., 2006; Vendrame et al., 2006), diabetes (Tong et al.,
2017), and hypertension (McMaster et al., 2015) that could
impede neurorepair.
Untreated hypertensive mice presented a reduced astrocytes
density in the peri-infarct area compared to non-hypertensive
mice at D9 and, on the contrary, increased astrocytes density in
treated hypertensive mice compared to untreated mice at D40.
Moreover, untreated and treated hypertensive mice had increased
astrocytes density between D9 and D40. Given the complex
role of astrocytes following stroke, this increased glial scar at
D40 is difficult to interpret as being a simple epiphenomenon
or as a key event resulting in the absence of neurorepair
(Morrison and Filosa, 2019).
Post-stroke dementia will eventually affect 25% of patients
(Iadecola, 2013). This is a particular important heath issue since it
is the second cause of cognitive decline after Alzheimer’s disease
and that there is no current treatment to prevent or cure the
disease. Still too few studies evaluate this aspect because of the
need for models that must be maintained over time, complying
with the increased early mortality when adding comorbidity
(Poittevin et al., 2015). We found that diabetic mice with
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pMCAo presented altered spatial memory at Barnes maze but
not non-diabetic pMCAO mice (Mangin et al., 2019). Structural
alterations in the hippocampus, which is involved in information
processing related to spatial memory, have already been observed
after focal brain ischemia, with neurodegeneration in the CA1
zone in particular (Wang et al., 2004). Diabetes by itself can
also decrease neuronal density (Artola et al., 2005; Amin et al.,
2013) and impair long-term potentiation in rats (Artola et al.,
2005). In our model, both conditions (pMCAo + diabetes)
were necessary to alter the Barnes Maze, that also evaluates
brain plasticity (Martin et al., 2000), but again hADMSC did
not prevent spatial memory impairment in those mice. MSC
beneficial effects rely partly on the promulgation of neurogenesis
(Leu et al., 2010; Bao et al., 2011), limitation of neuronal death
(Gutiérrez-Fernández et al., 2013), and angiogenesis promotion
(Wang et al., 2008) none of which having been observed in
treated mice. We failed to show spatial memory impairment in
our hypertensive mice after 16 weeks of mild elevated blood
pressure, although impaired vasoreactivity after 8 weeks was
evidenced just as for diabetic mice. If the duration of the
hypertension was appropriate to induce a sensorimotor deficit,
we cannot exclude that both the duration of hypertension
and/or the time points chosen to assess the Barnes maze test
were inadequate and that a later evaluation would have been
more contributive.
CONCLUSION
These negative results are of utmost importance, given
the importance of vascular risk factors in stroke patients.
Comorbid animals should be part of all preclinical stroke
studies and could avoid considerable unnecessary costs
in clinical studies. The next preclinical study will focus
on time administration and other models of vascular
risk factors. If hADMSC prove then to be efficient, we
will have the opportunity, by comparing the molecular
pathways, to explore the in depths-mechanisms involved by
these human ADMSC.
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